New driver of atherosclerosis offers potential as therapeutic target

June 19, 2014
New driver of atherosclerosis offers potential as therapeutic target
Dr. Shaul,UT Southwestern Medical Center. Credit: UT Southwestern

A new driver of atherosclerosis has been identified by researchers at UT Southwestern Medical Center. This molecule, known as 27HC (27-hydroxycholesterol), has been found to exacerbate the development of the condition, and may prove to be a promising therapeutic target.

Atherosclerosis is characterized by the build-up of lesions (or plaques) formed from lipids, such as cholesterol and fatty acids. Ruptured plaques can partially or completely block blood flow, potentially leading to a heart attack or stroke. A member of a larger family of molecules known as oxysterols, 27HC is produced during the normal breakdown of cholesterol and is known to accumulate in .

The new study, conducted by a team of UT Southwestern researchers led by senior author Dr. Philip Shaul, sought to identify the impact of 27HC on atherosclerosis. Dr. Shaul is Vice Chair for Research and Professor of Pediatrics, and Director of the Center for Pulmonary and Vascular Biology at UT Southwestern. The study's findings – first-authored by Dr. Michihisa Umetani, Assistant Professor of Pediatrics and Pharmacology – were recently published in Cell Metabolism.

Using animal models and other strategies, the researchers found that 27HC promotes the formation of atherosclerotic plaques, causing a doubling in the accumulation of lipids in the arterial wall. 27HC achieves this buildup through mechanisms mediated by estrogen receptors, which normally enable the to protect against the development and progression of atherosclerosis. By blocking estrogen receptors, 27HC prevents the beneficial effects of estrogen and promotes atherosclerosis.

"When 27HC is present, estrogen's protective effects are only observed at very high levels of the hormone," said Dr. Shaul, holder of the Associates First Capital Corporation Distinguished Chair in Pediatrics. "This result may explain why hormone therapy with estrogen does not provide cardiovascular benefit in women with pre-existing atherosclerosis, in which 27HC is abundant in the vascular wall."

Probing further into the underlying mechanisms, the researchers discovered that 27HC triggers inflammation in the arterial wall, a key step in the establishment of atherosclerotic plaques. This detrimental effect was characterized by exaggerated production of molecules that drive inflammation, called cytokines, and enhanced attachment on the of immune cells known as macrophages. It is the recruitment of macrophages that then accumulate lipids (such as cholesterol) that triggers the formation of atherosclerotic plaques.

"Although statins have had a dramatic impact on cardiovascular health by lowering cholesterol, we still need complementary methods to combat ," Dr. Shaul said. "Targeting 27HC, either by lowering the levels of this compound or by inhibiting its actions, could potentially provide a complementary approach to preventing vascular disease."

Explore further: New driver of breast cancer discovered

Related Stories

New driver of breast cancer discovered

November 7, 2013
A team of researchers at UT Southwestern has found that as cholesterol is metabolized, a potent stimulant of breast cancer is created – one that fuels estrogen-receptor positive breast cancers, and that may also defeat ...

High cholesterol fuels the growth and spread of breast cancer

November 28, 2013
A byproduct of cholesterol functions like the hormone estrogen to fuel the growth and spread of the most common types of breast cancers, researchers at the Duke Cancer Institute report.

Early atherosclerotic plaques regress when cholesterol levels are lowered

February 27, 2014
Early but not advanced forms of atherosclerotic plaques in the vessel wall disappear when the levels of 'bad' cholesterol are lowered, according to a study in mice from Karolinska Institutet, Sweden. The findings, published ...

New signal stabilizes atherosclerotic plaques

July 31, 2013
Atherosclerosis is an inflammatory disease with accumulation of cholesterol in the vessel walls. The atherosclerotic plaque is built up throughout life and when it ruptures it leads to heart attack or stroke. T cells are ...

Macrophage proliferation appears to drive progression of atherosclerosis

August 11, 2013
New insights into the development of vulnerable atherosclerotic plaques could lead to better treatment or prevention of heart attacks and strokes. In a report being published online in Nature Medicine, researchers at the ...

Recommended for you

Could aggressive blood pressure treatments lead to kidney damage?

July 18, 2017
Aggressive combination treatments for high blood pressure that are intended to protect the kidneys may actually be damaging the organs, new research from the University of Virginia School of Medicine suggests.

Quantifying effectiveness of treatment for irregular heartbeat

July 17, 2017
In a small proof-of-concept study, researchers at Johns Hopkins report a complex mathematical method to measure electrical communications within the heart can successfully predict the effectiveness of catheter ablation, the ...

Concerns over side effects of statins stopping stroke survivors taking medication

July 17, 2017
Negative media coverage of the side effects associated with taking statins, and patients' own experiences of taking the drugs, are among the reasons cited by stroke survivors and their carers for stopping taking potentially ...

Study discovers anticoagulant drugs are being prescribed against safety advice

July 17, 2017
A study by researchers at the University of Birmingham has shown that GPs are prescribing anticoagulants to patients with an irregular heartbeat against official safety advice.

Protein may protect against heart attack

July 14, 2017
DDK3 could be used as a new therapy to stop the build-up of fatty material inside the arteries

Heart study finds faulty link between biomarkers and clinical outcomes

July 14, 2017
Surrogate endpoints (biomarkers), which are routinely used in clinical research to test new drugs, should not be trusted as the ultimate measure to approve new health interventions in cardiovascular medicine, according to ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.